Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.

ABSTRACT: Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalesce

SUBMITTER: Lombardi A 

PROVIDER: S-EPMC7994748 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature